{"id":51,"date":"2022-05-22T13:46:33","date_gmt":"2022-05-22T17:46:33","guid":{"rendered":"https:\/\/carleton.ca\/ghostmanagement\/?page_id=51"},"modified":"2025-12-24T16:10:17","modified_gmt":"2025-12-24T21:10:17","slug":"publications","status":"publish","type":"page","link":"https:\/\/carleton.ca\/ghostmanagement\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"<h2><\/h2>\n<h2 style=\"text-align: center;\">Publications<\/h2>\n<h3>Articles<\/h3>\n<ul>\n<li>Dong, M., &amp; Gagnon, M.-A. (2025). Unveiling chemical industry secrets: Insights gleaned from scientific literatures that examine internal chemical corporate documents-A scoping review. <i>PloS One<\/i>, <i>20<\/i>(1), e0310116. <a href=\"https:\/\/doi.org\/10.1371\/journal.pone.0310116\">https:\/\/doi.org\/10.1371\/journal.pone.0310116<\/a><\/li>\n<\/ul>\n<div class=\"csl-bib-body\">\n<ul>\n<li>\n<div class=\"csl-bib-body\">\n<div class=\"csl-entry\">Grundy, Q. 2025. Delivering the script: The educational activities of medical device industry representatives as a knowledge management strategy. <i>Social Science &amp; Medicine<\/i>, <i>384<\/i>, 118565. <a href=\"https:\/\/doi.org\/10.1016\/j.socscimed.2025.118565\">https:\/\/doi.org\/10.1016\/j.socscimed.2025.118565<\/a><\/div>\n<\/div>\n<\/li>\n<li>Gagnon, M.-A. 2024. Commentary: Which Principles for a National Strategy for Rare Diseases? <em>Healthcare Policy<\/em> 19 (4): 27\u201331. <a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.longwoods.com%2Fcontent%2F27353%2Fcommentary-which-principles-should-apply-for-a-national-strategy-on-rare-diseases-&amp;data=05%7C02%7Cgrace.dupasquier%40rcaanc-cirnac.gc.ca%7C2af09490251949c4d9e308dcf906c33c%7C727ce8f2a756412ea4c695204ad68d84%7C0%7C0%7C638659055973408672%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=%2BmHeQL7X3xc%2B9vrJmnH8pKfobkP26OV%2FPvySzjnus%2B0%3D&amp;reserved=0\">https:\/\/www.longwoods.com\/content\/27353\/commentary-which-principles-should-apply-for-a-national-strategy-on-rare-diseases-<\/a><\/li>\n<li>Garc\u00eda Carrillo M, Gagnon M.-A. and Blaustein M. Editorial: Current priorities in health research agendas: tensions between public and commercial interests in prioritizing biomedical, social, and environmental aspects of health. <em>Frontiers in Medicine.<\/em> March 2024 Vol. 11 :1391982. doi: 10.3389\/fmed.2024.1391982. <a href=\"https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2024.1391982\/full\">https:\/\/www.frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2024.1391982\/full<\/a><\/li>\n<li>Lexchin J, Dong BM, Ramanathan A, Gagnon MA. Phase IV drug trials with a Canadian site: a comparison of industry-funded and non-industry-funded trials. <em>Int J Health Policy Manag. <\/em>March 2024; Vol. 13:8239. doi:10.34172\/ijhpm.2024.8239. <a href=\"https:\/\/www.ijhpm.com\/article_4576.html\">https:\/\/www.ijhpm.com\/article_4576.html\u00a0<\/a><\/li>\n<li>M.-A. Gagnon &amp; M.-H. Bacon.\u00a0 Le temps est venu d\u2019am\u00e9liorer la transparence \u00e0 l\u2019Agence de r\u00e9glementation de la lutte antiparasitaire de Sant\u00e9 Canada. <em>CMAJ<\/em> February 2024 196 (6), E-206-E208 (Translation of Gagnon and Bacon 2023),. <a href=\"https:\/\/www.cmaj.ca\/content\/196\/6\/E206\">https:\/\/www.cmaj.ca\/content\/196\/6\/E206<\/a><\/li>\n<li>Gagnon MA, Dong M. What did the scientific literature learn from internal company documents in the pharmaceutical industry? A scoping review. <em>Cochrane Evidence Synthesis and Methods<\/em>. 2023;1(3):e12011: \u00a0<a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2Ffull%2F10.1002%2Fcesm.12011&amp;data=05%7C02%7CGRACEDUPASQUIER%40cmail.carleton.ca%7C2ae6c0aae9a34a26142f08dd04247e2e%7C6ad91895de06485ebc51fce126cc8530%7C0%7C0%7C638671276957245343%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=iANoL%2BmB7LyfYzpunA0dGWuejVOQqVW%2F3RgzIOyAeYA%3D&amp;reserved=0\">https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/cesm.12011<\/a><\/li>\n<li>Gagnon, M.-A. &amp; Bacon, M.-H. (2023). Time to Improve Transparency at Health Canada\u2019s Pest Management Regulatory Agency. <i>CMAJ<\/i>, <i>195<\/i>(46), E1583\u2013E1584. <a href=\"https:\/\/doi.org\/10.1503\/cmaj.231089\">https:\/\/doi.org\/10.1503\/cmaj.231089<\/a><\/li>\n<\/ul>\n<\/div>\n<div class=\"csl-bib-body\">\n<div>\n<div class=\"csl-bib-body\">\n<div class=\"csl-bib-body\">\n<div>\n<div class=\"csl-bib-body\">\n<ul>\n<li class=\"csl-entry\">Grundy, Q., Quanbury, A., Hart, D., Chaudhry, S., Tavangar, F., Lexchin, J., Gagnon, M.-A., &amp; Tadrous, M. (2023). Prevalence and Nature of Manufacturer-Sponsored Patient Support Programs for Prescription Drugs in Canada: A Cross-Sectional Study. <i>CMAJ<\/i>, <i>195<\/i>(46), E1565\u2013E1576. <a href=\"https:\/\/doi.org\/10.1503\/cmaj.230841\">https:\/\/doi.org\/10.1503\/cmaj.230841<\/a><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<ul>\n<li class=\"csl-entry\">Bensussan, H., Durand, C., &amp; Rikap, C. (2023). 100 years of Corporate Planning. From Industrial Capitalism to Intellectual Monopoly Capitalism through the lenses of the Harvard Business Review (1922-2021). Universit\u00e9 de Gen\u00e8ve. <a href=\"https:\/\/archive-ouverte.unige.ch\/unige:171107\">https:\/\/archive-ouverte.unige.ch\/unige:171107<\/a><\/li>\n<\/ul>\n<\/div>\n<ul>\n<li>Gagnon, M.-A. (2023). Commentary: Reconsidering Pharmaceutical Research and Development Investments. <i>Healthcare Policy<\/i>, <i>18<\/i>(3). <a href=\"https:\/\/www.longwoods.com\/content\/27037\/healthcare-policy\/commentary-reconsidering-pharmaceutical-research-and-development-investments\">https:\/\/www.longwoods.com\/content\/27037\/healthcare-policy\/commentary-reconsidering-pharmaceutical-research-and-development-investments<\/a><\/li>\n<li>Bacon, M.-H., Vandelac, L., Gagnon, M.-A., &amp; Parent, L. (2023). Poisoning Regulation, Research, Health, and the Environment: The Glyphosate-Based Herbicides Case in Canada. Toxics, 11(2), Article 2. <a href=\"https:\/\/doi.org\/10.3390\/toxics11020121\">https:\/\/doi.org\/10.3390\/toxics11020121<\/a><\/li>\n<li>Garc\u00eda Carrillo M., Testoni F., Gagnon M.-A., Rikap C., Blaustein M.. Academic dependency: the influence of the prevailing international biomedical research agenda on Argentina\u2019s CONICET. <em>Heliyon<\/em>. 2022 Nov 1;8(11):e11481: <a href=\"https:\/\/t.co\/je5ozgGvqH\">https:\/\/t.co\/je5ozgGvqH<\/a><\/li>\n<li>Testoni F.E., Garc\u00eda Carrillo M., Gagnon M.-A., Rikap C., Blaustein M. Whose shoulders is health research standing on? Determining the key actors and contents of the prevailing biomedical research agenda. <em>PLOS ONE<\/em>. 2021 Apr 7;16(4): e0249661: <a href=\"https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0249661\">https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0249661<\/a><\/li>\n<li>Lexchin J., Bero L.A., Davis C., Gagnon M.-A. Achieving greater independence from commercial influence in research. <em>BMJ<\/em>. 2021 Mar 9;372:n370 : <a href=\"https:\/\/www.bmj.com\/content\/372\/bmj.n370\">https:\/\/www.bmj.com\/content\/372\/bmj.n370<\/a><\/li>\n<li>Gagnon M.-A. La Canada face \u00e0 l\u2019iniquit\u00e9 vaccinale globale\u202f: se situer du mauvais c\u00f4t\u00e9 de l\u2019histoire. <em>Rev Interventions \u00c9conomiques \/ Papers in Political Economy<\/em> [Internet]. 2021 Nov 1 [cited 2022 Nov 25]; (Hors-s\u00e9rie. Transformations). Available from: <a href=\"https:\/\/journals.openedition.org\/interventionseconomiques\/14794\">https:\/\/journals.openedition.org\/interventionseconomiques\/14794<\/a><\/li>\n<li class=\"csl-bib-body\">\n<div class=\"csl-entry\">Gagnon, M.-A. (2021). Understanding the Battle for Universal Pharmacare in Canada; Comment on \u201cUniversal Pharmacare in Canada.\u201d <i>International Journal of Health Policy and Management<\/i>, <i>10<\/i>(3), 168\u2013171. <a href=\"https:\/\/doi.org\/10.34172\/ijhpm.2020.40\">https:\/\/doi.org\/10.34172\/ijhpm.2020.40<\/a><\/div>\n<\/li>\n<li class=\"csl-bib-body\">\n<div class=\"csl-entry\">Gagnon, M.-A. (2019). Co-pay cards in Canada: Improving choice or institutionalizing bribes? <i>CMAJ<\/i>, <i>191<\/i>(45), E1235\u2013E1236. <a href=\"https:\/\/doi.org\/10.1503\/cmaj.191447\">https:\/\/doi.org\/10.1503\/cmaj.191447<\/a><\/div>\n<\/li>\n<li class=\"csl-bib-body\">\n<div class=\"csl-entry\">Charbonneau, M., &amp; Gagnon, M.-A. (2018). Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs. <i>Health Policy<\/i>, <i>122<\/i>(12), 1295\u20131301. <a href=\"https:\/\/doi.org\/10.1016\/j.healthpol.2018.08.006\">https:\/\/doi.org\/10.1016\/j.healthpol.2018.08.006<\/a><\/div>\n<\/li>\n<li>Lexchin J., Kohler J.C., Gagnon M.-A., Crombie J., Thacker P., Shnier A.. Combating corruption in the pharmaceutical arena. <em>Indian J Med Ethics<\/em>. 2018 Sep;3(3):234\u20139: \u00a0<a href=\"https:\/\/ijme.in\/articles\/combating-corruption-in-the-pharmaceutical-arena\/\">https:\/\/ijme.in\/articles\/combating-corruption-in-the-pharmaceutical-arena\/<\/a><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h3>Book Chapters<\/h3>\n<ul>\n<li>Gagnon, MA, 2024. \u201cThe anatomy of Big Pharma\u201d. In Primrose D, Loeppky Rand Chang R. (eds) <em>The Routledge Handbook of the Political Economy of Health and Healthcare<\/em>. London and New York: Routledge: pp.245-258. <a href=\"https:\/\/www-taylorfrancis-com.proxy.library.carleton.ca\/chapters\/edit\/10.4324\/9781003017110-23\/anatomy-big-pharma-marc-andr%C3%A9-gagnon?context=ubx&amp;refId=2bea9d3f-cba0-413b-8f2b-40afe00b6b9d\">https:\/\/www.taylorfrancis.com\/chapters\/edit\/10.4324\/9781003017110-23\/anatomy-big-pharma-marc-andr%C3%A9-gagnon?context=ubx&amp;refId=d01bc120-9b80-4c0a-aa95-1ca753bf6be6<\/a><\/li>\n<li>Gagnon M.-A. Combatting Corruption in the Pharmaceutical Sector. In: Faintuch J, Faintuch S, editors. <em>Integrity of Scientific Research: Fraud, Misconduct and Fake News in the Academic, Medical and Social Environment<\/em> [Internet]. Cham: Springer International Publishing; 2022: p. 477\u201386. Available from: <a href=\"https:\/\/doi.org\/10.1007\/978-3-030-99680-2_47\">https:\/\/doi.org\/10.1007\/978-3-030-99680-2_47<\/a><\/li>\n<li>Gagnon M.-A. Ghost management as a central feature of accumulation in corporate capitalism\u202f: The case of the global pharmaceutical sector. In: Marl\u00e8ne Benquet, Th\u00e9o Bourgeron, editors. <em>Accumulating Capital Today<\/em>. London and New York: Routledge; 2021. <a href=\"https:\/\/www.taylorfrancis.com\/chapters\/edit\/10.4324\/9781003089513-15\/ghost-management-central-feature-accumulation-corporate-capitalism-marc-andr%C3%A9-gagnon\">https:\/\/www.taylorfrancis.com\/chapters\/edit\/10.4324\/9781003089513-15\/ghost-management-central-feature-accumulation-corporate-capitalism-marc-andr%C3%A9-gagnon<\/a><\/li>\n<\/ul>\n<h3>E-Books<\/h3>\n<ul>\n<li>Blaustein, M., Gagnon, M.-A., Garcia Carrillo, M., eds. (2024). <em>Current priorities in health research agendas: Tensions between public and commercial interests in prioritizing biomedical, social, and environmental aspects of health<\/em>. Lausanne: Frontiers Media SA. <a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.frontiersin.org%2Fresearch-topics%2F48714%2Fcurrent-priorities-in-health-research-agendas-tensions-between-public-and-commercial-interests-in-prioritizing-biomedical-social-and-environmental-aspects-of-health%2Farticles&amp;data=05%7C02%7CGRACEDUPASQUIER%40cmail.carleton.ca%7C82dee39390a045c5343308dcc37e6936%7C6ad91895de06485ebc51fce126cc8530%7C0%7C0%7C638600194900214212%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=8tUYsPJDTusx7fSt%2F3mUoKZapk8MoxfT7%2FzSich2Fxs%3D&amp;reserved=0\">https:\/\/www.frontiersin.org\/research-topics\/48714\/current-priorities-in-health-research-agendas-tensions-between-public-and-commercial-interests-in-prioritizing-biomedical-social-and-environmental-aspects-of-health\/articles<\/a><\/li>\n<\/ul>\n<h3>Policy Briefs &amp; Technical Reports<\/h3>\n<ul>\n<li>\n<div class=\"csl-bib-body\">\n<div class=\"csl-entry\">Marc-Andr\u00e9 Gagnon <i>Pharmacare and Access to Medicines in Canada: Is Bill C-64 a Step in the Right Direction?<\/i> Perspectives Journal. November 7, 2024. <a href=\"https:\/\/perspectivesjournal.ca\/pharmacare-bill-c64\/\">https:\/\/perspectivesjournal.ca\/pharmacare-bill-c64\/<\/a><\/div>\n<\/div>\n<\/li>\n<li>Marc-Andr\u00e9 Gagnon and Quinn Grundy. <em>Preferred Provider Networks in Employer-Sponsored Drug Insurance Sector; <\/em><em>Some necessary considerations. <\/em>Submission to Ontario Ministry of Finance. October 21 2024. <a href=\"https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/Brief-PPN-Ontario_QG-FInal.pdf\">https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/Brief-PPN-Ontario_QG-FInal.pdf<\/a><\/li>\n<li>Marc-Andr\u00e9 Gagnon. <em>Pharmacare and Access to Medicines in Canada; A Policy Brief. <\/em>Submission to Canadian Senate Standing Committee on Social Affairs, Science and Technology. September 13 2024. <a href=\"https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/PMRA-Submission-Revised-16082023-1-1.pdf\">https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/PMRA-Submission-Revised-16082023-1-1.pdf<\/a><\/li>\n<li>Marc-Andr\u00e9 Gagnon, Marie-H\u00e9l\u00e8ne Bacon and Louise Vandelac. <em>Reinforcing regulation and transparency at Health Canada\u2019s PMRA; some necessary considerations<\/em>. Submission to Health Canada. August 1 2023. <a href=\"https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/PMRA-Submission-Revised-16082023-.pdf\">https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/PMRA-Submission-Revised-16082023-.pdf<\/a><\/li>\n<li>Marc-Andr\u00e9 Gagnon. <em>Mergers and Acquisitions in the Pharmaceutical Sector; Some Necessary Considerations<\/em>. Submission to US Federal Trade Commission Pharmaceutical Task Force, Project No. P212900, June 25 2021. <a href=\"https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/Submission-on-MAs-in-the-pharmaceutical-sector.pdf\">https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/Submission-on-MAs-in-the-pharmaceutical-sector.pdf<\/a><\/li>\n<li>Marc-Andr\u00e9 Gagnon, Anil Varughese et Nahya Awada. <em>Developing a National Strategy for Rare Diseases in Canada; Some Necessary Considerations. <\/em>Submitted to Health Canada, March 26 2021. <a href=\"https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/Submission-on-rare-disease.pdf\">https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/Submission-on-rare-disease.pdf<\/a><\/li>\n<li>Marc-Andr\u00e9 Gagnon et Joel Lexchin. <em>Soumission quant \u00e0 la prise en consid\u00e9ration d\u2019une nouvelle capacit\u00e9 de biofabrication pour le Canada; De la n\u00e9cessit\u00e9 de repenser nos mani\u00e8res de faire. <\/em>\u00a0Pr\u00e9sent\u00e9 \u00e0 Innovation, Sciences et D\u00e9veloppement \u00c9conomique Canada, 12 mars 2021. <a href=\"https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/Memoir-about-Biomanufacturing-in-Canada-3.pdf\">https:\/\/carleton.ca\/ghostmanagement\/wp-content\/uploads\/Memoir-about-Biomanufacturing-in-Canada-3.pdf<\/a><\/li>\n<\/ul>\n<h3>Op-Eds &amp; Commentaries<\/h3>\n<div class=\"csl-bib-body\">\n<ul>\n<li>Marc-Andr\u00e9 Gagnon. \u00ab\u00a0Penser l\u2019assurance m\u00e9dicaments pour l\u2019int\u00e9r\u00eat de la population\u00a0\u00bb <em>La Presse<\/em>. 6 d\u00e9cembre 2023\u00a0: <a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.lapresse.ca%2Fdialogue%2Fopinions%2F2023-12-06%2Freplique%2Fpenser-l-assurance-medicaments-pour-l-interet-de-la-population.php&amp;data=05%7C02%7CGRACEDUPASQUIER%40cmail.carleton.ca%7C82dee39390a045c5343308dcc37e6936%7C6ad91895de06485ebc51fce126cc8530%7C0%7C0%7C638600194900224264%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=oSU6hDIb2m8fr%2BwJ2zJ5pkZPN0n5QW31ycSUhwCdru4%3D&amp;reserved=0\">https:\/\/www.lapresse.ca\/dialogue\/opinions\/2023-12-06\/replique\/penser-l-assurance-medicaments-pour-l-interet-de-la-population.php<\/a><\/li>\n<li class=\"csl-entry\">Rehn, T. (2023, November 27). Nouveaux OGM, ou quand les consultations publiques deviennent une mascarade. <i>Le Devoir<\/i>. <a href=\"https:\/\/www.ledevoir.com\/opinion\/idees\/802714\/idees-nouveaux-ogm-ou-quand-consultations-publiques-deviennent-mascarade\">https:\/\/www.ledevoir.com\/opinion\/idees\/802714\/idees-nouveaux-ogm-ou-quand-consultations-publiques-deviennent-mascarade<\/a>\u00a0<em>[not affiliated with the GM Research Group]\u00a0<\/em><\/li>\n<\/ul>\n<\/div>\n<ul>\n<li>Marc-Andr\u00e9 Gagnon. &#8220;Quelles mains sont aux commandes de la recherche m\u00e9dicale?&#8221; <em>Le Devoir<\/em>, 25 juin 2021\u00a0: <a href=\"https:\/\/www.ledevoir.com\/opinion\/idees\/613608\/etude-des-interets-commerciaux-lies-de-pres-a-la-recherche-medicale\">https:\/\/www.ledevoir.com\/opinion\/idees\/613608\/etude-des-interets-commerciaux-lies-de-pres-a-la-recherche-medicale<\/a><\/li>\n<li>Marc-Andr\u00e9 Gagnon. &#8220;La suspension des brevets sur les vaccins; Faire partie de la solution&#8221;. <em>Options Politiques<\/em>, 27 mai 2021\u00a0: <a href=\"https:\/\/policyoptions.irpp.org\/magazines\/may-2021\/la-suspension-des-brevets-sur-les-vaccins-faire-partie-de-la-solution\/\">https:\/\/policyoptions.irpp.org\/magazines\/may-2021\/la-suspension-des-brevets-sur-les-vaccins-faire-partie-de-la-solution\/<\/a><\/li>\n<li>Joel Lexchin, Barbara Mintzes, Kelly Holloway, Marc-Andr\u00e9 Gagnon. \u201cGuidelines governing Canadian doctors\u2019 relationships with pharma companies under\u00a0review\u201d. <em>The Conversation, <\/em>November 12 2020: <a href=\"https:\/\/theconversation.com\/guidelines-governing-canadian-doctors-relationships-with-pharma-companies-under-review-149519\">https:\/\/theconversation.com\/guidelines-governing-canadian-doctors-relationships-with-pharma-companies-under-review-149519<\/a><\/li>\n<li>Joel Lexchin, Barbara Mintzes,Lisa Bero, MA Gagnon, Quinn Grundy(2020). &#8220;Canada\u2019s COVID-19 Vaccine Task Force needs better transparency about potential conflicts of interest&#8221;. <em>The Conversation. October 8 2020: <\/em><a href=\"https:\/\/theconversation.com\/canadas-covid-19-vaccine-task-force-needs-better-transparency-about-potential-conflicts-of-interest-147323\">https:\/\/theconversation.com\/canadas-covid-19-vaccine-task-force-needs-better-transparency-about-potential-conflicts-of-interest-147323<\/a><\/li>\n<li>Marc-Andr\u00e9 Gagnon and Louise Vandelac, 2020. &#8220;Privil\u00e9gier l\u2019industrie pharmaceutique au d\u00e9triment de la recherche publique?&#8221; <em>Le Devoir. <\/em>3 septembre 2020: <a href=\"https:\/\/www.ledevoir.com\/opinion\/idees\/585254\/sante-privilegier-l-industrie-pharmaceutique-au-detriment-de-la-recherche-publique\">https:\/\/www.ledevoir.com\/opinion\/idees\/585254\/sante-privilegier-l-industrie-pharmaceutique-au-detriment-de-la-recherche-publique<\/a><\/li>\n<\/ul>\n<h3>News Articles<\/h3>\n<ul>\n<li>Crowe, K. (2023, March 23). Pharma lobby paid StatCan for reports then used in industry PR push. <i>The Breach<\/i>. Retrieved March 27, 2023, from <a href=\"https:\/\/breachmedia.ca\/pharma-lobby-paid-statistics-canada-reports-used-industry-pr-push\/\">https:\/\/breachmedia.ca\/pharma-lobby-paid-statistics-canada-reports-used-industry-pr-push\/<\/a>.<\/li>\n<\/ul>\n<h3>Lectures<\/h3>\n<ul>\n<li>Gagnon, M.-A. (2023, March). <i>Une pilule difficile \u00e0 avaler<\/i>. <i>Coeur des sciences<\/i>. Montreal; Quebec. Retrieved March 27, 2023, from\n<div><a href=\"https:\/\/tv.uqam.ca\/conference-penurie-medicaments-une-pilule-difficile-avaler\">https:\/\/tv.uqam.ca\/conference-penurie-medicaments-une-pilule-difficile-avaler<\/a>.<\/div>\n<\/li>\n<\/ul>\n<h3>Documentaries\/TV Broadcasts<\/h3>\n<ul>\n<li>\n<div class=\"csl-bib-body\">\n<div class=\"csl-entry\">Gignac, B. (Director). (2023). Prix des m\u00e9dicaments: Le bon dosage. In <i>L\u2019enqu\u00eate McSween<\/i>. T\u00e9l\u00e9-Qu\u00e9bec. <a href=\"https:\/\/video.telequebec.tv\/player\/45410\/stream?assetType=episodes\">https:\/\/video.telequebec.tv\/player\/45410\/stream?assetType=episodes<\/a>\u00a0<em>[not affiliated with the GM Research group]<\/em><\/div>\n<\/div>\n<\/li>\n<\/ul>\n<h3>Podcast Appearances<\/h3>\n<ul>\n<li>\n<div class=\"csl-bib-body\">\n<div class=\"csl-entry\">McClelland, J., &amp; Gagnon, M.-A. (November 13, 2024). <i>The Continuing Battle for Universal Pharmacare with Marc-Andr\u00e9 Gagnon<\/i> [Broadcast]. <a href=\"https:\/\/perspectivesjournal.ca\/the-continuing-battle-for-universal-pharmacare-with-marc-andre-gagnon\/\">https:\/\/perspectivesjournal.ca\/the-continuing-battle-for-universal-pharmacare-with-marc-andre-gagnon\/<\/a><\/div>\n<\/div>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Publications Articles Dong, M., &amp; Gagnon, M.-A. (2025). Unveiling chemical industry secrets: Insights gleaned from scientific literatures that examine internal chemical corporate documents-A scoping review. PloS One, 20(1), e0310116. https:\/\/doi.org\/10.1371\/journal.pone.0310116 Grundy, Q. 2025. Delivering the script: The educational activities of medical device industry representatives as a knowledge management strategy. Social Science &amp; Medicine, 384, 118565. [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_mi_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Publications - Ghost Management<\/title>\n<meta name=\"description\" content=\"Publications Articles Dong, M., &amp; Gagnon, M.-A. (2025). Unveiling chemical industry secrets: Insights gleaned from scientific literatures that examine\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/carleton.ca\/ghostmanagement\/publications\/\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/carleton.ca\/ghostmanagement\/publications\/\",\"url\":\"https:\/\/carleton.ca\/ghostmanagement\/publications\/\",\"name\":\"Publications - Ghost Management\",\"isPartOf\":{\"@id\":\"https:\/\/carleton.ca\/ghostmanagement\/#website\"},\"datePublished\":\"2022-05-22T17:46:33+00:00\",\"dateModified\":\"2025-12-24T21:10:17+00:00\",\"description\":\"Publications Articles Dong, M., &amp; Gagnon, M.-A. (2025). Unveiling chemical industry secrets: Insights gleaned from scientific literatures that examine\",\"breadcrumb\":{\"@id\":\"https:\/\/carleton.ca\/ghostmanagement\/publications\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/carleton.ca\/ghostmanagement\/publications\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/carleton.ca\/ghostmanagement\/publications\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/carleton.ca\/ghostmanagement\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/carleton.ca\/ghostmanagement\/#website\",\"url\":\"https:\/\/carleton.ca\/ghostmanagement\/\",\"name\":\"Ghost Management\",\"description\":\"Carleton University\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/carleton.ca\/ghostmanagement\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publications - Ghost Management","description":"Publications Articles Dong, M., &amp; Gagnon, M.-A. (2025). Unveiling chemical industry secrets: Insights gleaned from scientific literatures that examine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/carleton.ca\/ghostmanagement\/publications\/","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/carleton.ca\/ghostmanagement\/publications\/","url":"https:\/\/carleton.ca\/ghostmanagement\/publications\/","name":"Publications - Ghost Management","isPartOf":{"@id":"https:\/\/carleton.ca\/ghostmanagement\/#website"},"datePublished":"2022-05-22T17:46:33+00:00","dateModified":"2025-12-24T21:10:17+00:00","description":"Publications Articles Dong, M., &amp; Gagnon, M.-A. (2025). Unveiling chemical industry secrets: Insights gleaned from scientific literatures that examine","breadcrumb":{"@id":"https:\/\/carleton.ca\/ghostmanagement\/publications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/carleton.ca\/ghostmanagement\/publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/carleton.ca\/ghostmanagement\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/carleton.ca\/ghostmanagement\/"},{"@type":"ListItem","position":2,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/carleton.ca\/ghostmanagement\/#website","url":"https:\/\/carleton.ca\/ghostmanagement\/","name":"Ghost Management","description":"Carleton University","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/carleton.ca\/ghostmanagement\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":{"banner_image_type":"none","banner_button":"no"},"_links":{"self":[{"href":"https:\/\/carleton.ca\/ghostmanagement\/wp-json\/wp\/v2\/pages\/51"}],"collection":[{"href":"https:\/\/carleton.ca\/ghostmanagement\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/carleton.ca\/ghostmanagement\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/carleton.ca\/ghostmanagement\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/carleton.ca\/ghostmanagement\/wp-json\/wp\/v2\/comments?post=51"}],"version-history":[{"count":3,"href":"https:\/\/carleton.ca\/ghostmanagement\/wp-json\/wp\/v2\/pages\/51\/revisions"}],"predecessor-version":[{"id":472,"href":"https:\/\/carleton.ca\/ghostmanagement\/wp-json\/wp\/v2\/pages\/51\/revisions\/472"}],"wp:attachment":[{"href":"https:\/\/carleton.ca\/ghostmanagement\/wp-json\/wp\/v2\/media?parent=51"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}